Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy

Andreasen N , Carpenter W , Kane J , Lasser R , Marder S , Weinberger D (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry162: 441-449

Ballenger J C , Davidson J R , Lecrubier Y , Nutt D J , Baldwin D S , den Boer J A , Kasper S , Shear M K (1998) Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry59 (Suppl. 8): 47-54

Barnes T R E , Curzon D A (1994) Long-acting depot antipsychotics: a risk-benefit assessment. Drug Safety10: 464-479

Burton S (2006) Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol20 (Suppl. 6): 6-19

Chue P (2006) The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol20 (Suppl. 6): 38-56

Chue P , Eerdekens M , Augustyns I , Lachaux B , Molcan P , Eriksson L , Pretorius H , David A S (2005) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol15: 111-117

David A , Adams C E , Eisenbruch M , Quraishi S , Rathbone J (2005) Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrate Database Syst Rev2: CD00307

Ferrier I N (2001) Characterizing the ideal antidepressant therapy to achieve remission. J Clin Psychiatry62 (Suppl. 26): 10-15

Fleischhacker W W , Eerdekens M , Karcher K , Remington G , Llorca P M , Chrzanowski W , Martin S , Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry64: 1250-1257

Frank E , Prien R F , Jarrett R B , Keller M B , Kupfer D J , Lavori P W , Rush A J , Weissman M M (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Arch Gen Psychiatry48: 851-855

Harding C M , Brooks G W , Ashikaga T , Strauss J S , Breier A (1987) The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry144: 727-735

Harrison G , Hopper K , Craig T , Laska E , Siegel C , Wanderling J , Dube K C , Ganev K , Giel R , an der Heiden W , Holmberg S K , Janca A , Lee P W , Leon C A , Malhotra S , Marsella A J , Nakane Y , Sartorius N , Shen Y , Skoda C , Thara R , Tsirkin S J , Varma V K , Walsh D , Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry178: 506-517

Kissling W , Kane J , Barnes T , Dencker S , Fleischhacker W , Goldstein M , Johnson D , Marder S , Muller-Spahn F , Tegeler J , Wistedt B , Woggon B (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In Kissling W (ed.), Guidelines for neuroleptic relapse prevention in schizophrenia. Springer-Verlag, Berlin, Heidelberg: 155-163

Kordy H , Kramer B , Palmer R L , Papezova H , Pellet J , Richard M , Treasure J (2002) Remission, recovery, relapse, and recurrence in eating disorders: conceptualization and illustration of a validation strategy. J Clin Psychol58: 833-846

Kraepelin E (1919) Dementia Praecox and Paraphrenia. Translated and edited by R B Barclay , E S Livingston , Edinburgh

Lasser R A , Bossie C A , Gharabawi G M , Kane J M (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res77: 215-227

Lieberman J , Jody D , Geisler S , Alvir J , Loebel A , Szymanski S , Woerner M , Borenstein M (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry50: 369-376

Lieberman J A , Stroup T S , McEvoy J P , Swartz M S , Rosenheck R A , Perkins D O , Keefe R S , Davis S M , Davis C E , Lebowitz B D , Severe J , Hsiao J K (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med353: 1209-1223

Lindenmayer J P , Eerdekens E , Berry S A , Eerdekens M (2004) Safety and efficacy of long-acting risperidone in schizophrenia: a 12-, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry65: 1084-1089

Loebel A D , Lieberman J A , Alvir J M , Mayerhoff D I , Geisler S H , Szymanski S R (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry149: 1183-1188

Nasrallah H , Lasser N (2006) Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol20 (Suppl. 6): 57-61

Ogawa K , Miya M , Watarai A , Nakazawa M , Yuasa S , Utena H (1987) A long-term follow-up study of schizophrenia in Japan - with special reference to the course of social adjustment. Br J Psychiatry151: 758-765

Sheehan D (2001) Defining remission in generalized anxiety disorder: venlfaxine extended release comparative data. J Clin Psychiatry62: 26-31

Turner M , Stewart D (2006) Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol20 (Suppl. 6): 20-37

Turner M , Eerdekens E , Jacko M , Eerdekens M (2004) Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol19: 241-249.